The DMRTA1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited population of near-haploid HAP1 cells with targeted disruption of the DMRTA1 gene. This polyclonal knockout model provides a heterogeneous pool of gene-edited cells, enabling pooled functional genomics and loss-of-function studies. The product is designed for investigation of DMRTA1’s role in cellular processes without the need for single-cell cloning, and is suitable for gene expression, protein, and phenotypic analyses.
HAP1 cells originate from the KBM-7 chronic myeloid leukemia line and maintain a near-haploid karyotype, with fibroblast-like morphology and hematopoietic lineage characteristics. Their haploid genome simplifies genetic analyses by eliminating allelic complexity, making them a preferred host for CRISPR-based knockout studies. HAP1 cells are widely used for investigating signal transduction, cancer biology, and drug targets, providing a robust and well-characterized background for DMRTA1 disruption.
DMRTA1 encodes a DM domain transcription factor that participates in the sex determination pathway, acting downstream of SRY and SOX9 and cooperating with NR5A1 and DMRT1. It binds DNA through its DM domain and interacts with other DMRT proteins and transcriptional co-regulators to regulate gene expression during gonad development and cellular differentiation. Although its downstream targets are largely uncharacterized, DMRTA1 is thought to control developmental genes and sex-specific markers, with its activity modulated by hormonal signals.
Disrupting DMRTA1 in the HAP1 background offers a clean genetic system to study its transcriptional network and protein interactions. The knockout model recapitulates aspects of disorders of sex development and infertility, and may also inform testicular cancer biology. Within the hematopoietic context, DMRTA1 loss-of-function could reveal roles in proliferation or differentiation, extending knowledge beyond classical sex determination functions. The absence of a wild-type allele simplifies interpretation of phenotypic and molecular changes.
These polyclonal knockout cells are suited for RT-qPCR and western blot validation, ChIP for DNA-binding studies, and luciferase reporter assays to probe target gene regulation. RNA-seq enables transcriptome-wide analysis of DMRTA1-dependent gene expression, while cell proliferation assays assess growth phenotypes. The cells can also be used in drug screening to identify modulators of sex determination pathways. For further details, contact Ascent Research.
